secwatch / observer
8-K filed May 19, 2025, 7:59 PM ET ticker RPRX CIK 0001802768
M&A confidence high sentiment neutral materiality 0.65

Royalty Pharma plc (RPRX): M&A transaction — Royalty Pharma closes acquisition of RP LLC; $200M cash, shares, and $380M debt assumed

Royalty Pharma plc

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Royalty Pharma plc: Amended and restated the articles of association of Royalty Pharma Holdings Ltd, adopted as of May 16, 2025, concurrently with the consummation of the Transaction (effective 2025-05-16).

Change
charter amendment
Effective
2025-05-16
Exact text from the filing
Concurrently with the consummation of the Transaction, pursuant to the terms of the Purchase Agreement, the articles of association of RPH were amended and restated in their entirety by a special resolution of the shareholders of RPH and written class consents of each of the holder of the class C ordinary share of RPH and the holder of the class D ordinary share of RPH, and were adopted as of May 16, 2025 (the "RPH A&R Articles of Association").
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Royalty Pharma plc: Amended and restated the articles of association of Royalty Pharma plc to provide additional rights to redesignate Class B ordinary shares into deferred shares and refine calling of general meetings and class consents (effective 2025-05-12).

Change
charter amendment
Effective
2025-05-12
Exact text from the filing
In connection with the Transaction, the articles of association of the Company were amended and restated in their entirety by a special resolution passed by the shareholders of the Company at the Annual General Meeting and Special Meeting of Shareholders held on May 12, 2025 and a written class consent of the holders of the Class B ordinary shares of the Company (the "Company A&R Articles of Association").
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Royalty Pharma plc completed an acquisition involving Sellers (of RP LLC) for $200,000,000 of cash, less the aggregate amount of management fee payments ... and 24,530,266 non-voting Class E ordinary shares of RPH (closed 2025-05-16).

Action
acquisition
Counterparty
Sellers (of RP LLC)
Consideration
$200,000,000 of cash, less the aggregate amount of management fee payments ... and 24,530,266 non-voting Class E ordinary shares of RPH
Closing
2025-05-16
Exact text from the filing
of RP LLC from the Sellers. Pursuant to the Purchase Agreement, the aggregate consideration paid to, or at the direction of, the Sellers in the Transaction consisted of (i) $200,000,000 of cash, less the aggregate amount of management fee payments in respect of calendar year 2025 made to and actually received by RP Management and RP LLC and their respective
View on SEC.gov

Browse all governance changes →

Royalty Pharma plc filing history →

Source: SEC EDGAR
accession 0000950103-25-006186
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.